UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000014671
Receipt number R000016877
Scientific Title Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer
Date of disclosure of the study information 2014/07/28
Last modified on 2014/07/28 11:01:20

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer

Acronym

Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer

Scientific Title

Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer

Scientific Title:Acronym

Phase II study of hypofractionated stereotactic body radiation therapy for prostate cancer

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The aim is to determine the efficacy of hypofractionated stereotactic body radiation therapy for localized prostate cancer.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

the incidence of delayed adverse events at 5 years

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

irradiation

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

50 years-old <=

Age-upper limit

80 years-old >

Gender

Male

Key inclusion criteria

1)adenocaricnoma of the prostate which was pathologically confirmed
2) low risk group or intermediate risk group (T1-T2c and PSA =<20 ng/mL and Gleason score =<7)
3)neoadjuvant hormonal therapy for 3-12 months has been undertaken in patients with intermediate risk group
4)age:>=50,<80 years
5)Performance status:0-1
6)gold markers have been inserted
7)informed consent has been obtained

Key exclusion criteria

1)Patients who have had any other cancer within the past 5 years
2)Patients who have uncontrollable diabetes mellitus
3)Patients who have serious comorbidities such as collagen disease, heart disease, interstitial pneumonia, liver cirrhosis
4)patients who have a psychological problem
5)patients who had previously received pelvic irradiation
6)patients who had previously received pelvic surgery
7)patients who had previously received TURP, orchiectomy, or HIFU
8)patients who had previously received chemotherapy for prostate cancer
9)patients who have Crohn's disease or ulcerative colitis
10)patients who require concomitant anticoagulant therapy
11)IPSS at registration>=20

Target sample size

20


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Akitomo Sugawara

Organization

Tokai University Hachioji Hospital

Division name

Radiation Oncology

Zip code


Address

1838 Ishikawa-machi, Hachioji, Tokyo

TEL

042-639-1111

Email

h4411@wave.plala.or.jp


Public contact

Name of contact person

1st name
Middle name
Last name Akitomo Sugawara

Organization

Tokai University Hachioji Hospital

Division name

Radiation Oncology

Zip code


Address

1838 Ishikawa-machi, Hachioji, Tokyo

TEL

042-639-1111

Homepage URL


Email

h4411@wave.plala.or.jp


Sponsor or person

Institute

Radiation Oncology, Tokai University Hachioji Hospital

Institute

Department

Personal name



Funding Source

Organization

N/A

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2014 Year 07 Month 28 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2014 Year 05 Month 27 Day

Date of IRB


Anticipated trial start date

2014 Year 07 Month 29 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2014 Year 07 Month 28 Day

Last modified on

2014 Year 07 Month 28 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016877


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name